WVE — Wave Life Sciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1631574 ·
Last close
$2.84
Market Cap
$560.13M
52W High
$21.73
52W Low
$2.77
ADV30
2,910,815
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 13,158,000 | — | -66,047,000 | -61,912,000 | 507,930,000 | 197,315,000 | 105,994,000 |
| Jun 2026 | 2,272,000 | — | -73,802,000 | -69,355,000 | 558,321,000 | 368,008,000 | 104,801,000 |
| Mar 2026 | 38,246,000 | — | -31,298,000 | -26,087,000 | 583,544,000 | 544,591,000 | 71,814,000 |
| Dec 2025 | 17,245,000 | — | -56,467,000 | -53,179,000 | 638,499,000 | 602,068,000 | 120,142,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-207,053,000
Investing CF
$-234,750,000
Financing CF
$442,985,000
CapEx
$-1,585,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.07
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,483,590,000
Inventory
—
Receivables
$12,000,000
ST Investments
$233,434,000
EBIT TTM
$-227,614,000
Pretax Income TTM
$-210,533,000
Interest Exp TTM
—
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$70,921,000
EBITDA
$-224,190,000
Free Cash Flow
$-132,660,128
Enterprise Value
$320,573,984
Total Cash
$430,748,992
Total Debt
$43,271,000
Shares Out
197,228,968
Trailing EPS
$-1.07
Book Value
$2.04
ROE
-78.8%
ROA
-38.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 42,727,000 | -215,383,000 | -204,378,000 | 638,499,000 | 120,142,000 | 518,357,000 | -187,493,000 |
| Dec 2024 | 108,302,000 | -110,403,000 | -97,008,000 | 352,207,000 | 142,692,000 | 209,515,000 | -151,026,000 |
| Dec 2023 | 113,305,000 | -67,996,000 | -57,513,000 | 274,949,000 | 235,319,000 | 39,630,000 | -19,431,000 |
| Dec 2022 | 3,649,000 | -162,720,000 | -161,823,000 | 146,386,000 | 191,477,000 | -45,091,000 | -127,781,000 |
TTM Snapshot
Revenues TTM
$65,371,000
NetIncome TTM
$-202,473,000
OpCashFlow TTM
—
Assets (Latest)
$558,321,000
Forward EPS
$-1.16
Max Pain — expiry 2028-01-21
max pain strike: $3.00 · spot: $2.77 · call oi: 2,457 · put oi: 690
Expected Move to 2028-01-21:
±$1.84
(66.43%) —
implied range
$0.93 –
$4.61
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZVRA | ZEVRA THERAPEUTICS, INC. | $559.34M | $9.40 | — |
| ANL | Adlai Nortye Group Ltd. | $556.80M | $9.48 | — |
| AVBP | ArriVent BioPharma, Inc. | $552.92M | $10.69 | — |
| CLYM | Climb Bio, Inc. | $574.46M | $9.78 | — |
| ACRS | Aclaris Therapeutics, Inc. | $536.11M | $3.38 | — |
News headlines (Yahoo Finance, 1h cache)
WAVE Life Sciences Targets Genetic Liver Disease With WVE-008 RNA Editing Program
2026-11-04 19:14 · Yahoo
Wave Life Sciences Ltd. Q3 2026 Earnings Call Summary
2026-10-28 00:30 · Yahoo
Wave Life Sciences (WVE) Q3 2026 Earnings Call Transcript
2026-10-27 18:58 · Yahoo
WAVE Life Sciences Q3 Earnings Call Highlights
2026-10-27 17:05 · Yahoo
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
2026-10-27 11:40 · Yahoo
Wave Life Sciences: Q3 Earnings Snapshot
2026-10-27 11:35 · Yahoo
WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path
2026-10-22 03:02 · Yahoo
Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
2026-10-20 12:30 · Yahoo
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
2026-10-19 12:30 · Yahoo
Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views
2026-10-17 10:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.